Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

It’s been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

CNBC’s Jim Cramer suggested on Tuesday that NVIDIA Corp. (NASDAQ:NVDA) may have reached a key turning point after the stock ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

BofA notes that yesterday morning, the FDA issued a new decision determining that the shortage of Eli Lilly’s (LLY) tirzepatide was resolved.

HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth services ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...